Dynamic Technology Lab Private Ltd Has $711,000 Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Dynamic Technology Lab Private Ltd boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 309.0% during the 4th quarter, HoldingsChannel reports. The firm owned 19,150 shares of the company’s stock after buying an additional 14,468 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Amphastar Pharmaceuticals were worth $711,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after buying an additional 493 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after acquiring an additional 871 shares in the last quarter. Huntington National Bank increased its holdings in shares of Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company’s stock valued at $50,000 after purchasing an additional 361 shares during the period. TD Private Client Wealth LLC lifted its position in shares of Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after purchasing an additional 388 shares in the last quarter. Finally, KBC Group NV boosted its holdings in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH opened at $26.61 on Monday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a one year low of $25.73 and a one year high of $53.96. The business’s 50-day moving average price is $30.24 and its two-hundred day moving average price is $39.18. The company has a market capitalization of $1.27 billion, a P/E ratio of 8.87, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 27.10% of the stock is currently owned by company insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.